Merck Sharp + Dohme Corp.

G.d. Searle & Company

Serenete Corporation

Merck + Co., Inc.

Methylgene, Inc.

Helen Y Chen

Mark Andrew Russell

Barbara B Chen

James W Malecha

Thomas Dale Penning

Yan Guo

Peter Gerrard Ruminski

Christopher W Plummer

Timothy Allen Blizzard

Michael John Clare

Barbara A Pio

Julie M Miyashiro

Joseph Gerace Rico

Stella S Yu

Duane E DeMong

Harry R Chobanian

Richard A Haack

Frank P DiNinno

Tesfaye Biftu

Thomas Edward Rogers

Michael W Miller

Dong Xiao

Haifeng Tang

Linda Brockunier

Zhiyong Hu

William J Greenlee

Richard M Weier

William K Hagmann

Ish K Khanna

Alexander Pasternak

Paul E Finke

Xianhai Huang

Steven L Colletti

Feroze Ujjainwalla

Jinlong Jiang

Younong Yu

Zhicai Wu

Francis J Koszyk

James J Perkins

Milton L Hammond

Jian Liu

Deping Wang

Arkadii Vaisburg

Ping Liu

Jason M Cox

Fa-Xiang Ding

Liangqin Guo

Nizal S Chandrakumar

Mark E Layton

Songnian Lin

Alan Frank Gasiecki

Yong Zhang

Hong Liu

Ronald M Kim

Zhi-Cai Shi

Shawn P Walsh

John S Debenham

Jing Su

Anthony K Ogawa

Shuzhi Dong

Wanying Sun

Tao Yu

De-Yi Yang

Richard Berger

Xiangdong Xu

Shashidhar N Rao

Timothy A Blizzard

Brian T Campbell

Weiguo Liu

Stephen Hermann Docter

Christopher James Bungard

Weidong Pan

Michael J Kelly, Iii

Yi Yu

Kevin Michael Belyk

Jiayi Xu

Stephane Raeppel

Sookhee Nicole Ha

Min K Park

Jessica Frie

Anilkumar G Nair

Kevin D Dykstra

Aurash Shahripour

Michael Mannion

Walter Won

Mihir Mandal

Ting Zhang

Mehul F Patel

Libo Xu

Nelo R Rivera

Jubrail Rahil

Alejandro Crespo

Katherine Young

Zhiqiang Guo

Bart Harper

Yi Zang

Frederic Gaudette

Rui Zhang

Jason Eugene Imbriglio

Hongwu Wang

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Chromane amidine monobactam compounds for the treatment of bacterial infections

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

A food preparation device or system which utilizes pre-packaged food containers to prepare a food item for consumption.

Modularized food preparation device and tray structure for use thereof

A food preparation device or system which utilizes pre-packaged food containers to prepare a food item for consumption. The food preparation device is structured to receive multiple pre-packaged containers. Additionally, the food preparation device includes one or more processors to verify that each of the multiple containers include one or more ingredients for preparing a selected dish, and further that an order in which the multiple containers are individually received in the base corresponds to a sequence in which the individual food items of the multiple containers are to be introduced into a cooking receptacle during preparation of the dish.

System and method for operating a food preparation device

[5,6]&#x2014;fused bicyclic antidiabetic compounds

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

A food preparation device or system which includes the following: (i) a base dimensioned to hold food containers and includes a first opening to receive the food containers and a second opening; (ii) an extraction mechanism to extract food items from each container in the base, through the second opening and to a preparation receptacle; (iii) a heating mechanism in the preparation receptacle; and (iv) one or more processors and memory containing instructions that, when executed cause the food preparation device or system to prepare the food items for consumption.

Food preparation device

The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is &#x2014;O&#x2014;, &#x2014;N(R), &#x2014;C(R)(R) or &#x2014;C(O)&#x2014;; and Y is &#x2014;O&#x2014;, &#x2014;N(R), &#x2014;C(R)(R) or &#x2014;C(O)&#x2014; and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ACS, secondary prevention of myocardial infarction or stroke, or PAD. 

Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists

This invention relates to compounds of Formula I-VI having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Inhibitors of the Renal Outer Medullary Potassium channel

Substituted bicyclic beta-lactams of Formula I: (I), are &#x3b2;-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with &#x3b2;-lactam antibiotics. In particular, the compounds can be employed with a &#x3b2;-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to &#x3b2;-lactam antibiotics due to the presence of the &#x3b2;-lactamases.

&#x3b2;-lactamase inhibitors

This invention provides novel &#x3b2;-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammomium groups. The compounds inhibit three classes of &#x3b2;-lactamases and synergize the antibacterial effects of &#x3b2;-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the &#x3b2;-lactam antibiotics as a result of the presence of the &#x3b2;-lactamases.

Inhibitors of beta-lactamase

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

Estrogen receptor modulators

Growing community of inventors

Marlboro, NJ, United States of America

Helen Y Chen